Region Vaesterbotten

The Department of Rheumatology at Region Vaesterbotten is conducting studies on hereditary transthyretin amyloidosis and its cardiac manifestations, aiming to evaluate novel treatments that can halt disease progression and improve heart function.

• Evaluation of disease-modifying agents for ATTRv polyneuropathy
• Assessment of cardiac outcomes in ATTR-CM patients
• Biomarker-driven trials for early detection
• Combination therapy safety and efficacy

These investigations integrate cardiology and metabolic expertise to address a growing need for effective therapies in this rare, multisystem disorder.

Researchers are testing innovative therapies across a spectrum of solid tumours and haematologic malignancies, including breast cancer, non‑small cell lung cancer, and prostate cancer, with goals such as improving survival, reducing recurrence, and refining personalized treatment strategies.

• Targeted agents for HER2‑mutated lung cancer
• Immunotherapy duration in high‑risk melanoma
• Combination regimens for advanced gastric cancer with FGFR2b overexpression
• Maintenance strategies in multiple myeloma
• Adjuvant hormonal therapy in early‑stage breast cancer

The program emphasizes precision medicine, leveraging genetic markers and novel drug combinations to enhance outcomes for patients with diverse tumour types.

The site supports studies on conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and rare brain tumours, seeking to slow disease progression, preserve cognitive function, and explore new therapeutic pathways.

• Evaluating AMX0035 in ALS progression
• Semaglutide impact on early Alzheimer's cognition
• Targeted therapy for papillary craniopharyngioma
• Combination immunotherapy for medulloblastoma
• Biomarker validation in rare CNS tumors

These efforts combine cutting‑edge imaging, molecular diagnostics, and patient‑focused outcomes to address unmet needs in neurological health.

A range of trials focus on coronary artery disease, atrial fibrillation, and metabolic disorders such as type 2 diabetes, with objectives that include reducing major adverse cardiovascular events, preventing post‑operative arrhythmias, and improving glycaemic control.

• Dual antiplatelet therapy after CABG
• Early cryoballoon ablation for persistent AF
• SGLT2 inhibitor dapagliflozin to lower post‑operative AF
• Metformin trial for preeclampsia prolongation
• Renin inhibitor aliskiren in C3 glomerulopathy

By integrating cardiology, endocrinology, and renal expertise, the research aims to deliver safer, more effective interventions for common chronic diseases.

The department conducts focused investigations on ultra‑rare disorders, including fibrodysplasia ossificans progressiva and Langerhans cell histiocytosis, evaluating innovative therapies that could transform patient care.

• IPN60130 efficacy in preventing heterotopic ossification
• Salvage treatment strategies for multisystem LCH
• Aliskiren versus ACEi in complement‑mediated kidney disease
• Beta‑blocker use in COPD without cardiac disease
• Vaccination safety in children at risk for pneumococcal disease

These projects highlight a commitment to addressing unmet medical needs through targeted drug development and collaborative international networks.